VitaSpring Biomedical Co. Ltd. Stock price

Equities

VSBC

US92851B1026

Biotechnology & Medical Research

Market Closed - OTC Markets 02:03:41 2023-08-11 pm EDT 5-day change 1st Jan Change
15 USD +36.24% Intraday chart for VitaSpring Biomedical Co. Ltd. -.--% -.--%
Sales 2021 0.25 Sales 2022 5.61 Capitalization 2.89B
Net income 2021 - Net income 2022 1M EV / Sales 2021 2,936,169,226 x
Net cash position 2021 45.4K Net Debt 2022 356K EV / Sales 2022 515,149,430 x
P/E ratio 2021
-2,570 x
P/E ratio 2022
2,282 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 41.23%
More Fundamentals * Assessed data
Dynamic Chart
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022 CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022 CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2022 CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2022 CI
VitaSpring Biomedical Co. Ltd. Auditor Raises 'Going Concern' Doubt CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021 CI
QuantuMDx Group Limited announced that it has received ?15 million in funding from VitaSpring Biomedical Co. Ltd. CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2021 CI
Vitaspring Biomedical Co. Ltd. Announces Management Changes CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2021 CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2021 CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter Ended October 31, 2020 CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2020 CI
VitaSpring Biomedical Co. Ltd. announced that it expects to receive $0.082342 million in funding CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2020 CI
More news
1 year
11.01
Extreme 11.01
16.00
3 years
8.00
Extreme 8
19.50
5 years
0.38
Extreme 0.38
19.50
10 years
0.38
Extreme 0.38
19.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20-01-20
Chairman 70 20-01-20
Chief Tech/Sci/R&D Officer - 20-01-20
Members of the board TitleAgeSince
Chairman 70 20-01-20
More insiders
Date Price Change Volume

Delayed Quote OTC Markets, August 11, 2023 at 02:03 pm EDT

More quotes
Vitaspring Biomedical Co. Ltd. is focused on cell medical industry. The Company is engaged in the business of developing and marketing products that promote wellness and a healthy lifestyle. The Company invests in research and development of stem cell applications in regenerative medicine, establish advanced medical research centers and cell production centers and provides GTP standard stem cell preparations for the development of cellular drugs. The Company is focused on the fields of medicine, preventive health care, beauty, and anti-aging. It is also focused on developing X.MSC cytopharmaceuticals.
More about the company
  1. Stock
  2. Equities
  3. Stock VitaSpring Biomedical Co. Ltd. - OTC Markets